Immune cells expressing an antigen binding receptor and a chimeric costimulatory receptor

Patent metadata

Field	Value
Publication number	US-11890300-B2
Application number	US-201716465750-A
Country	US
Kind code	B2
Filing date	Dec 11, 2017
Priority date	Dec 15, 2016
Publication date	Feb 6, 2024
Grant date	Feb 6, 2024

Abstract

The present invention provides an immune effector cell that comprises a chimeric antigen receptor (CAR) specific for a tag of a tagged polypeptide, wherein said polypeptide binds to an antigen of a target cell, and a chimeric costimulatory receptor (CCR) specific for a further antigen. The CCR is not able to mediate said immune response on its own but boosts the immune response of said immune effector cell triggered by the CAR.

First claim

The invention claimed is:

1. A T cell comprising:
a) a chimeric antigen receptor (CAR) comprising a first antigen binding domain, a first transmembrane domain and a first cytoplasmic signaling domain comprising at least one CD3ζ cytoplasmic signaling domain and at least one 4-1BB co-stimulatory signaling domain, wherein said first antigen binding domain binds to a tag of a tagged polypeptide, and wherein the polypeptide of said tagged polypeptide binds to an antigen expressed on the surface of a target cell to be killed; and
b) a chimeric costimulatory receptor (CCR) comprising a second antigen binding domain, a second transmembrane domain and a second cytoplasmic part comprising at least one CD28 co-stimulatory domain and/or at least one 4-1BB co-stimulatory domain or a combination thereof, wherein said CCR does not comprise CD3ζ, and wherein said second antigen binding domain binds to a further antigen, and wherein said further antigen is not expressed on the surface of said target cell.

2. The T cell according to claim 1 , wherein said target cell is a cancer cell.

3. The T cell according to claim 1 , wherein said second cytoplasmic part comprises two 4-1BB co-stimulatory domains or two CD28 co-stimulatory domains.

4. The T cell according to claim 1 , wherein the polypeptide of said tagged polypeptide is an antibody or antigen binding fragment thereof, wherein said antibody or antigen binding fragment thereof binds to said antigen expressed on the surface of said target cell, and wherein the tag of said tagged polypeptide is a hapten.

5. The T cell according to claim 1 , wherein the polypeptide of said tagged polypeptide is an antigen binding moiety (ABM), wherein the tag of said tagged polypeptide is a linker/label epitope (LLE) of a target cell binding molecule (TCBM), and wherein said CAR is an anti-linker/label epitope chimeric antigen receptor (anti-LLE CAR) comprising:
I) an extracellular linker/label epitope (LLE) binding domain;
II) a transmembrane domain; and
III) a cytoplasmic signaling domain comprising at least one CD3ζ cytoplasmic signaling domain and at least one 4-1BB co-stimulatory signaling domain,
wherein said extracellular LLE binding domain binds a target cell binding molecule (TCBM) comprising:
i) an antigen binding moiety (ABM), wherein said ABM binds specifically to said antigen expressed on the surface of said target cell;
ii) a label moiety (LaM), wherein said LaM is a naturally occurring molecule in a subject or a derivative thereof; and
iii) a linker moiety (LiM) conjugating said ABM and said LaM, thereby forming a linker/label epitope (LLE),
wherein said extracellular LLE binding domain binds said LLE with a higher preference than said naturally occurring molecule.

6. The T cell according to claim 1 , wherein said further antigen is expressed on the surface of another cell that is not in a disease state.

7. The T cell according to claim 6 , wherein said further antigen is CD20 and the other cell is a B cell.

8. The T cell according to claim 1 , wherein said further antigen is not expressed on a surface of a cell.

9. The T cell according to claim 8 , wherein said further antigen is dextran.

10. The T cell according to claim 9 , wherein said second antigen binding domain comprises the amino acid sequence of SEQ ID NO: 19, and wherein said second cytoplasmic part comprises the amino acid sequence of SEQ ID NO: 21.

Assignees

• Miltenyi Biotec Gmbh
• Miltenyi Biotec Bv & Co Kg

Inventors

• Lock Dominik
• Assenmacher Mario
• Kaiser Andrew

Classifications

• A61K40/4271

  Melanoma antigens · CPC title

• A61K40/4258

  Gangliosides, e.g. GM2, GD2 or GD3 · CPC title

• A61K40/4221

  CD20 · CPC title

• A61K40/4211

  CD19 or B4 · CPC title

• A61K40/31

  Chimeric antigen receptors [CAR] · CPC title